LHDX News and Press, Lucira Health Inc. From 12/06/22

Lucira COVID-19 & Flu Test is the first and only combination over-the-counter (OTC) self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in Canada. Lucira’s 99% accurate, di...

PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swab Positive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visit Equipment-free Lucira platform requires no capital investment or calibration and...

Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costs Lucira partners with Pfizer to increase awareness of the high risk factors for severe C...

Lucira Health ( NASDAQ: LHDX ) stock fell ~34% on Tuesday after the company's Q3 results . GAAP Gross Loss widened to -$99.56M, compared to -$1.48M in Q3 2021. The company said the increases in GAAP gross loss and negative gross margin were mainly due to a char...

Lucira Health, Inc. (LHDX) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Greg Chodaczek – Gilmartin Group Erik Engelson – President and Chief Executive Officer Dan George – Chief Financial Officer Co...

Lucira Health press release ( NASDAQ: LHDX ): Q3 GAAP EPS of -$3.15. Revenue of $34.4M (+129.3% Y/Y). Cash and Cash Equivalents as of September 30, 2022 was $39.8M. For further details see: Lucira Health GAAP EPS of -$3.15, revenue of $34.4M

EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported fina...

EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health ...

The shares of MedTech firm Lucira Health, Inc. ( NASDAQ: LHDX ) spiked pre-market Wednesday after the company announced interim data from a pilot study designed to evaluate its combined Chlamydia and gonorrhoeae assays, which are integrated into a rapid point of care test (POC)....

EMERYVILLE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health” or “Lucira”), a medical technology company, today announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trach...